SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020

SMi Group 13 - 14 May 2020, London, UK.
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London. Part of Europe's leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year's event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.

Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.

The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

The benefits of attending

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:
  • DELVE into the latest work in complex formulation for subcutaneous delivery
  • BENCHMARK against leading pharma companies working to enhance device design and development
  • UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
  • ENGAGE in industry case studies on design controls, human factors and parenteral formulation
  • EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops

Who should attend

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

Featured Speakers

  • Alexander Zuern,Device testing manager, Novartis International AG
  • Andrew Warrington, Project Leader & Patient Advocate, Novartis
  • Benjamin Werner,Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Bjorg K Hunter, Regulatory Manager, Devices, GSK
  • Blake Green, Senior Manager Regulatory Affairs, Amgen
  • Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
  • Christopher Muenzer, Senior Device Technology Manager, Novartis
  • Joel Richard,Head of Technical & Pharmaceutical Operations, MedinCell
  • Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
  • Rebecca Moses, Director, Core Human Factors Inc.
  • Rupal Nguyen, Principal Engineer, Allergan
  • StefaniaRagone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
  • Tina Arien, Principal Scientist, Janssen Pharmaceutica
  • Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

Early-bird rates

  • Book by 31st January and save £400
  • Book by 28th February and save £300
  • Book by 29th March and save £200

For further information and to register, please visit:
http://www.injectable-drug-delivery.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Pfizer and BioNTech share positive early data on l…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vac...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...

Steroid found to improve survival of critically il…

A new international study published today has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery...

Bayer and Informed Data Systems Inc. (One Drop) jo…

Bayer and Informed Data Systems Inc. (One Drop), a US-based digital health company, today announced that they have entered into an agreement to jointly develop digital he...

Abbott's fast, $5, 15-minute, easy-to-use COVID-19…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test f...